SEC Filings

SEC Filings
Home / SEC Filings

SEC Filings

Form 10-K
PROTALIX BIOTHERAPEUTICS, INC. filed this Form 10-K on 03/16/2017
Document Outline
Entire Document (4068 KB)
Subdocument 1 - 10-K - 10-K
Page 1 - UNITED STATES
Page 2 - FORM 10-K
Page 3 - PART I
Page 4 - N/A
Page 5 - N/A
Page 6 - Our Strategy
Page 7 - ProCellEx: Our Proprietary Protein Expression System
Page 8 - Competitive Advantages of Our ProCellEx Protein Expression System
Page 9 - Significantly Lower Capital and Production Costs.
Page 10 - Our Pipeline Drug Candidates
Page 11 - Phase I/II Clinical Data; Efficacy Results:
Page 12 - Phase I/II Pharmacokinetics and Immunogenicity:
Page 13 - alidornase alfa Development Program
Page 14 - OPRX-106; Oral antiTNF for the treatment of inflammatory diseases
Page 15 - OPRX-106 Development Program
Page 16 - N/A
Page 17 - N/A
Page 18 - N/A
Page 19 - N/A
Page 20 - N/A
Page 21 - N/A
Page 22 - N/A
Page 23 - Law for the Encouragement of Capital Investments, 1959
Page 24 - N/A
Page 25 - N/A
Page 26 - N/A
Page 27 - N/A
Page 28 - You should carefully consider the risks described below together with the other information included
Page 29 - We may find it difficult to enroll patients in our clinical trials, which could cause significant de
Page 30 - We may not obtain the necessary U.S., EMA or other worldwide regulatory approvals to commercialize o
Page 31 - We have only limited experience in regulatory affairs, and some of our drug candidates may be based
Page 32 - Our strategy, in certain cases, is to enter into collaboration agreements with third parties to leve
Page 33 - The manufacture of our products is an exacting and complex process, and if we or one of our material
Page 34 - If we in-license drug candidates, we may delay or otherwise adversely affect the development of our
Page 35 - Our collaborations with outside scientists and consultants may be subject to restriction and change.
Page 36 - Reforms in the healthcare industry and the uncertainty associated with pharmaceutical pricing, reimb
Page 37 - Risks Related to Our Financial Condition and Capital Requirements
Page 38 - A substantial majority of our authorized shares of common stock under our certificate of incorporati
Page 39 - If we are unable to refinance or otherwise defease the remaining outstanding 4.5% convertible notes
Page 40 - We currently have no significant product revenues and may need to raise additional capital to operat
Page 41 - Future sales of our common stock could reduce our stock price.
Page 42 - Failure to maintain effective internal controls in accordance with Section 404 of the Sarbanes-Oxley
Page 43 - Risks Related to the Commercialization of Drug Products
Page 44 - We may enter into distribution arrangements and marketing alliances for certain products and any fai
Page 45 - Coverage and reimbursement may not be available for
Page 46 - Risks Related to Intellectual Property Matters
Page 47 - We rely on confidentiality agreements that could be breached and may be difficult to enforce which c
Page 48 - If we cannot meet requirements under our license agreements, we could lose the rights to our product
Page 49 - Because a certain portion of our expenses is incurred in New Israeli Shekels, our results of operati
Page 50 - Investors may have difficulties enforcing a U.S. judgment, including judgments based upon the civil
Page 51 - N/A
Page 52 - PART II
Page 53 - N/A
Page 54 - N/A
Page 55 - You should read the following discussion and analysis of our financial condition and results of oper
Page 56 - Critical Accounting Policies
Page 57 - Discontinued Operations
Page 58 - Share-Based Compensation
Page 59 - Convertible Notes
Page 60 - Selling, General and Administrative Expenses
Page 61 - Financial Expenses and Income
Page 62 - Future Funding Requirements
Page 63 - Contractual Obligations
Page 64 - Interest Rate Risk
Page 65 - N/A
Page 66 - N/A
Page 67 - PART IV
Page 68 - N/A
Page 69 - N/A
Page 70 - N/A
Page 71 - PROTALIX BIOTHERAPEUTICS, INC.
Page 72 - REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
Page 73 - PROTALIX BIOTHERAPEUTICS, INC.
Page 74 - PROTALIX BIOTHERAPEUTICS, INC.
Page 75 - PROTALIX BIOTHERAPEUTICS, INC.
Page 76 - PROTALIX BIOTHERAPEUTICS, INC.
Page 77 - PROTALIX BIOTHERAPEUTICS, INC.
Page 78 - PROTALIX BIOTHERAPEUTICS, INC.
Page 79 - PROTALIX BIOTHERAPEUTICS, INC.
Page 80 - PROTALIX BIOTHERAPEUTICS, INC.
Page 81 - PROTALIX BIOTHERAPEUTICS, INC.
Page 82 - PROTALIX BIOTHERAPEUTICS, INC.
Page 83 - PROTALIX BIOTHERAPEUTICS, INC.
Page 84 - PROTALIX BIOTHERAPEUTICS, INC.
Page 85 - PROTALIX BIOTHERAPEUTICS, INC.
Page 86 - PROTALIX BIOTHERAPEUTICS, INC.
Page 87 - PROTALIX BIOTHERAPEUTICS, INC.
Page 88 - PROTALIX BIOTHERAPEUTICS, INC.
Page 89 - PROTALIX BIOTHERAPEUTICS, INC.
Page 90 - PROTALIX BIOTHERAPEUTICS, INC.
Page 91 - PROTALIX BIOTHERAPEUTICS, INC.
Page 92 - PROTALIX BIOTHERAPEUTICS, INC.
Page 93 - PROTALIX BIOTHERAPEUTICS, INC.
Page 94 - PROTALIX BIOTHERAPEUTICS, INC.
Page 95 - PROTALIX BIOTHERAPEUTICS, INC.
Page 96 - PROTALIX BIOTHERAPEUTICS, INC.
Page 97 - PROTALIX BIOTHERAPEUTICS, INC.
Page 98 - PROTALIX BIOTHERAPEUTICS, INC.
Subdocument 2 - EX-23.1 - EXHIBIT 23.1
Page 1 - Exhibit 23.1
Subdocument 3 - EX-31.1 - EXHIBIT 31.1
Page 1 - EXHIBIT 31.1
Subdocument 4 - EX-31.2 - EXHIBIT 31.2
Page 1 - EXHIBIT 31.2
Subdocument 5 - EX-32.1 - EXHIBIT 32.1
Page 1 - EXHIBIT 32.1
Subdocument 6 - EX-32.2 - EXHIBIT 32.2
Page 1 - EXHIBIT 32.2
XBRL Item - EX-101.INS - XBRL INSTANCE DOCUMENT (What's this?)
XBRL Item - EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA (What's this?)
XBRL Item - EX-101.CAL - XBRL TAXONOMY EXTENSION CALCULATION LINKBASE (What's this?)
XBRL Item - EX-101.DEF - XBRL TAXONOMY EXTENSION DEFINITION LINKBASE (What's this?)
XBRL Item - EX-101.LAB - XBRL TAXONOMY EXTENSION LABEL LINKBASE (What's this?)
XBRL Item - EX-101.PRE - XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE (What's this?)
XBRL Viewer